Ide-cel's March 2021 FDA approval marks a significant advance in relapsed/refractory multiple myeloma treatment.
Philip McCarthy, MD
Advertisement
Articles by Philip McCarthy, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
Tr1X's Multiple Sclerosis Cell Therapy TRX319 Cleared for US Trial
2
Krystal Biotech’s Neurotrophic Keratitis Gene Therapy Viral Vector Secures FDA Platform Technology Designation
3
Around the Helix: Cell and Gene Therapy Company Updates – October 15, 2025
4
Patients Treated With Spur Therapeutics’ Gaucher Disease Gene Therapy FLT201 Maintain Clinical Benefit for Up to 2 Years
5
